KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Receivables: 2016-2025

Historic Change in Receivables for CRISPR Therapeutics AG (CRSP) over the last 8 years, with Mar 2025 value amounting to -$25.0 million.

  • CRISPR Therapeutics AG's Change in Receivables rose 87.50% to -$25.0 million in Q1 2025 from the same period last year, while for Dec 2024 it was -$45.0 million, marking a year-over-year decrease of 122.51%. This contributed to the annual value of -$175.0 million for FY2024, which is 187.50% down from last year.
  • As of Q1 2025, CRISPR Therapeutics AG's Change in Receivables stood at -$25.0 million, which was down 200.00% from $25.0 million recorded in Q4 2024.
  • CRISPR Therapeutics AG's Change in Receivables' 5-year high stood at $200.0 million during Q4 2023, with a 5-year trough of -$200.0 million in Q1 2024.
  • Its 3-year average for Change in Receivables is $0, with a median of $0 in 2024.
  • Over the last 5 years, CRISPR Therapeutics AG's Change in Receivables had its largest YoY gain of 408,263.27% in 2023, and its largest YoY loss of 411,664.71% in 2023.
  • CRISPR Therapeutics AG's Change in Receivables (Quarterly) stood at $153,000 in 2021, then tumbled by 132.03% to -$49,000 in 2022, then skyrocketed by 408,263.27% to $200.0 million in 2023, then slumped by 87.50% to $25.0 million in 2024, then skyrocketed by 87.50% to -$25.0 million in 2025.
  • Its Change in Receivables stands at -$25.0 million for Q1 2025, versus $25.0 million for Q4 2024 and -$200.0 million for Q1 2024.